The FDA has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes treatment Jentadueto (linagliptin/metformin hydrochloride), which combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet, taken twice-daily, to lower blood sugar in adults with type 2 diabetes.
Jentadueto is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. At the maximum dose, Jentadueto demonstrated placebo-corrected reductions in hemoglobin A1c levels of up to 1.7 percent (+0.1 percent for placebo and -1.6 percent for Jentadueto ). Jentadueto did not cause any meaningful change in body weight. Jentadueto can be used alone or in combination with a sulfonylurea, a commonly prescribed medication for type 2 diabetes.
Jentadueto is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine).
Jentadueto has not been studied in combination with insulin and therefore it is not known if it is safe and effective when used with insulin.